BiotechTube
Personal Genome Diagnostics

Personal Genome Diagnostics

Baltimore, United States· Est.
personalgenome.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $135.5M

Overview

Personal Genome Diagnostics (PGDx) is a commercial-stage precision oncology diagnostics company, now a subsidiary of Labcorp following its 2022 acquisition. Its core offering is the PGDx elio™ portfolio, which includes FDA-cleared and CE-IVD marked kitted solutions for tissue and liquid biopsy-based comprehensive genomic profiling, backed by proprietary bioinformatics. The company targets the global market for distributed cancer diagnostics, serving both clinical laboratories and biopharma partners through its products and services. Its strategy focuses on removing barriers to testing by enabling local labs to perform rapid, in-house genomic analysis to guide personalized treatment decisions.

Oncology

Technology Platform

The PGDx elio™ platform integrates distributed NGS-based assay kits (for tissue and liquid biopsy) with a proprietary, fully automated, cloud-based bioinformatics pipeline for comprehensive genomic profiling of 500+ cancer-related genes.

Funding History

3
Total raised:$135.5M
Series C$103.5M
Series B$21.5M
Series A$10.5M

Opportunities

The growing demand for decentralized, in-house comprehensive genomic profiling from hospital labs presents a major expansion opportunity.
Furthermore, transitioning its liquid biopsy assay from RUO to an FDA-cleared/CE-IVD diagnostic would allow PGDx to capture significant share in the high-growth non-invasive cancer testing market.

Risk Factors

Key risks include strategic and cultural integration challenges following the Labcorp acquisition, intense competition from both large reference labs and other distributed kit providers, and the regulatory and reimbursement hurdles associated with advancing its liquid biopsy assay to diagnostic status.

Competitive Landscape

PGDx competes in the comprehensive genomic profiling space against large centralized reference laboratories (e.g., Foundation Medicine, Guardant Health, Labcorp's own central lab) and other companies offering distributed NGS kit solutions (e.g., Illumina with TSO 500). Its differentiated value proposition is the combination of an FDA-cleared/CE-IVD kitted assay with a fully automated, proprietary bioinformatics platform.

More companies in United States →